12:00 AM
 | 
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amonafide L-malate: Phase III ongoing

Antisoma moved up the anticipated date for reporting data from its ongoing, open-label, international Phase III ACCEDE trial in over 420 patients to 1Q11 from June 2011. The trial is comparing 600 mg/m 2 IV AS1413 for 5 days plus cytarabine...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >